Cereno Scientific to open two new clinics to complete patient recruitment in the Phase II study of CS1 in PAH as top-line results are estimated in Q1 2024
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that further mitigation strategies have been activated for the Phase II study of CS1 in pulmonary arterial hypertension (PAH) due to slower patient recruitment than anticipated. Two new specialist clinics with large capacities are currently in the start-up phase to open to complete the recruitment of patients fulfilling the study criteria. Consequently, the timeline of the study estimates top-line results to be reported in Q1 2024.The Phase